Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Aug 25, 2017 3:30pm
359 Views
Post# 26623019

RE:Alternate Version to Lying Shorter Fantasy

RE:Alternate Version to Lying Shorter Fantasy33, you have hit the nail on the head. While I understand the weeping and wailing of those who bought above $3, they did not go thru the near bankruptcy misery that some of us did when the sp hit 7 cents. What we have witnessed over the last 5 years has been the build up of an incredible pipeline of products which one day will bring tremendous shareholder value.

PLI will soon have its first product approved, Pg followed quickly by IVIG and many others after that. This based on a novel manufacturing process which offers tremendous efficiencies in the use of plasma. The potential of the plasminogen franchise will be proved in coming months as clinical trials are completed in in both IV and SC apps and will be the envy of any may major pharma. The PPPS division alone will enable PLI to become cashflow positive by early 2019 and extremely profitable into the next decade as new products and additional production capacity are brought onstream.

The SMT platform will offer an order of magnitude more potential than the the PPPS platform. 4050 has not failed in any clinical trial. And in the case of IPF, 4050 has demonstrated the scope to be the standard of care drug for this hideous disease. We are probably only a few months away from seeing a couple of partnership deals in relation 4050. this will bring much needed cash. However it will also bring credibility to the SMT program which will be further enhanced when Alstrom results are released next month.

People are critical of Pierre Laurin but frankly he has done an amazing job in creating value for shareholders. yes, we are anxious for him to close deals so the company can address its cash needs before before becoming cashflow positive in 2019. For me the fact that PLI is on the cusp of having its first products approved and its first 4050 partnerships signed are what has instigated this very long sophisticated short attack on the company. hedge funds see the potential and the only way they can get shares at a reasonable price is to do what they are doing. It has been dirty with all the fake news and retailers are succombing. But the key driver of the current situation is the value that has been built and that lies inherent in PLI's pipeline. And that is due to Pierre Laurin, his vision and the team he has built at Prometic. I'm angry at the current sp but I'm not selling. I have every confidence Pierre and the Prometic team will deliver the goods and we will see a new sp high in coming months.
Bullboard Posts